Results 201 to 210 of about 60,399 (263)

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

Front Oncol
Kluitmans DJF, Melis JJTM, van den Bossche E, Ytsma J, de Roos JADM, van Linden OPJ, Grobben Y, Kooijman JJ, Zaman GJR.   +8 more
europepmc   +1 more source

Unraveling the RKIP-YY1 axis: immune crosstalk in the pathogenesis of metabolic disorders. [PDF]

Front Immunol
Alzaid F, Arefanian H, Bahman F, Albeloushi S, Alhamar G, Mohammad A, Hasan A, Al Madhoun A, Ahmad R, Al-Mulla F.   +9 more
europepmc   +1 more source

Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets. [PDF]

Front Oncol
Peng H, Li M, Peng YY, Li XL, Yang J, Sun QG, Song K.   +6 more
europepmc   +1 more source

Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation. [PDF]

Nat Commun
Jang DM, Boxer K, Ha BH, Tkacik E, Levitz T, Rawson S, Metivier RJ, Schmoker A, Jeon H, Eck MJ.   +9 more
europepmc   +1 more source

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. [PDF]

Signal Transduct Target Ther
Rozengurt E, Eibl G.
europepmc   +1 more source

The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

Clinical management and therapeutic development for the rare disease rhabdomyosarcoma. [PDF]

J Cancer
Ke TL, Chen L.
europepmc   +1 more source

The YYR (YY1- RKIP) Regulatory Axis in the pathogenesis of Cancer and Immune Evasion. [PDF]

J Exp Clin Cancer Res
Ung W, Bonavida B.
europepmc   +1 more source

Targeted design, synthesis, molecular dynamics, ADME and in -vitro anticancer assessment of oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAF^V600E inhibitors. [PDF]

Sci Rep
Singh AK, Kumar A, Singh H, Pathak P, Verma A, Khalilullah H, Jaremko M, Emwas AH, Novak J, Kumar P.   +9 more
europepmc   +1 more source

EC359 Enhances Trametinib Efficacy in <i>Ras</i>/<i>Raf</i>-Driven Ovarian Cancer by Suppressing LIFR Signaling. [PDF]

Biomolecules
Arnold WC, Panneerdoss DM, Subramani B, Mahajan M, Ebrahimi B, Ramirez P, Santhamma B, Viswanadhapalli S, Kost ER, Chen Y, Lai Z, Nair HB, Vadlamudi RK, Lyons YA.   +13 more
europepmc   +1 more source